7-HydroxyflavonolCAS# 492-00-2 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 492-00-2 | SDF | Download SDF |
PubChem ID | 5393152 | Appearance | Powder |
Formula | C15H10O4 | M.Wt | 254.2 |
Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 3,7-dihydroxy-2-phenylchromen-4-one | ||
SMILES | C1=CC=C(C=C1)C2=C(C(=O)C3=C(O2)C=C(C=C3)O)O | ||
Standard InChIKey | UWQJWDYDYIJWKY-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C15H10O4/c16-10-6-7-11-12(8-10)19-15(14(18)13(11)17)9-4-2-1-3-5-9/h1-8,16,18H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 7-Hydroxyflavonol can inhibit E6 binding to FADD and caspase 8. |
7-Hydroxyflavonol Dilution Calculator
7-Hydroxyflavonol Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.9339 mL | 19.6696 mL | 39.3391 mL | 78.6782 mL | 98.3478 mL |
5 mM | 0.7868 mL | 3.9339 mL | 7.8678 mL | 15.7356 mL | 19.6696 mL |
10 mM | 0.3934 mL | 1.967 mL | 3.9339 mL | 7.8678 mL | 9.8348 mL |
50 mM | 0.0787 mL | 0.3934 mL | 0.7868 mL | 1.5736 mL | 1.967 mL |
100 mM | 0.0393 mL | 0.1967 mL | 0.3934 mL | 0.7868 mL | 0.9835 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- (+/-)-2-Methyl-1-butanol
Catalog No.:BCN0140
CAS No.:137-32-6
- Syringetin 3-O-galactoside
Catalog No.:BCN0139
CAS No.:55025-56-4
- Cynatratoside E
Catalog No.:BCN0138
CAS No.:
- Bidenoside C
Catalog No.:BCN0137
CAS No.:700877-55-0
- 5,7-Dihydroxy-3',4',5'-trimethoxyflavanone
Catalog No.:BCN0136
CAS No.:62252-10-2
- Protocetraric acid
Catalog No.:BCN0135
CAS No.:489-51-0
- Castalin
Catalog No.:BCN0134
CAS No.:19086-75-0
- 3',4',7,8-Tetramethoxyflavone
Catalog No.:BCN0133
CAS No.:65548-55-2
- (+)-Lariciresinol 4'-O-beta-D-Glucopyranosyl-(1->3)-beta-D-glucopyranoside
Catalog No.:BCN0132
CAS No.:639857-95-7
- (-)-Cadin-4,10(15)-dien-11-oic acid
Catalog No.:BCN0131
CAS No.:1124353-23-6
- 2,3-Dehydrosilybin A
Catalog No.:BCN0130
CAS No.:25166-14-7
- Negundoside
Catalog No.:BCN0129
CAS No.:82451-20-5
- alpha-Bisabolol
Catalog No.:BCN0142
CAS No.:23089-26-1
- cis-Aconitic acid
Catalog No.:BCN0143
CAS No.:585-84-2
- Ergocristine
Catalog No.:BCN0144
CAS No.:511-08-0
- 3',4',7,8-Tetrahydroxyflavone
Catalog No.:BCN0145
CAS No.:3440-24-2
- Daphnin
Catalog No.:BCN0146
CAS No.:486-55-5
- 2',6'-Dihydroxy 4',4-dimethoxydihydrochalcone
Catalog No.:BCN0147
CAS No.:35241-54-4
- 2'-Hydroxyflavanone
Catalog No.:BCN0148
CAS No.:17348-76-4
- 3',4',7-Trihydroxyisoflavone
Catalog No.:BCN0149
CAS No.:485-63-2
- Maritimein
Catalog No.:BCN0150
CAS No.:490-54-0
- Candicine
Catalog No.:BCN0151
CAS No.:6656-13-9
- Comanthosid B
Catalog No.:BCN0153
CAS No.:70938-60-2
- Helenien
Catalog No.:BCN0154
CAS No.:547-17-1
Small molecule inhibitors of the HPV16-E6 interaction with caspase 8.[Pubmed:22300659]
Bioorg Med Chem Lett. 2012 Mar 1;22(5):2125-9.
High-risk strains of human papillomaviruses (HPVs) cause nearly all cases of cervical cancer as well as a growing number of head and neck cancers. The oncogenicity of these viruses can be attributed to the activities of their two primary oncoproteins, E6 and E7. The E6 protein has among its functions the ability to prevent apoptosis of infected cells through its binding to FADD and caspase 8. A small molecule library was screened for candidates that could inhibit E6 binding to FADD and caspase 8. Flavonols were found to possess this activity with the rank order of myricetin>morin>quercetin>kaempferol=galangin>>(apigenin, 7-Hydroxyflavonol, rhamnetin, isorhamnetin, geraldol, datiscetin, fisetin, 6-hydroxyflavonol). Counter screening, where the ability of these chosen flavonols to inhibit caspase 8 binding to itself was assessed, demonstrated that myricetin, morin and quercetin inhibited GST-E6 and His-caspase 8 binding in a specific manner. The structure-activity relationships suggested by these data are unique and do not match prior reports on flavonols in the literature for a variety of anticancer assays.
On the antioxidant properties of three synthetic flavonols.[Pubmed:17294818]
Pharmazie. 2007 Jan;62(1):72-6.
The antioxidant properties of a series of synthetic and natural flavonoids towards the oxygenated species superoxide radical anion (*O2-) enzimatically generated, were evaluated. 7-Hydroxyflavonol, 7,3'-dihydroxyflavonol and 3'-hydroxyflavonol were synthesised, with a systematic variation of the OH substitution on positions C3, C7, C3'and C4', and their respective antioxidative abilities compared to those of the already characterised natural flavonoids quercetin, kaempferol and rutin. The efficiency of *O2- deactivation by the flavonoids does not correlate with their respective determined oxidation potentials, suggesting that the pure one-electron-transfer-mechanism of *O2 quenching could not be the main scavenging process involved. Experimental evidence demonstrated that the possible inhibition of the *O2(-)-generator enzymatic system by the flavonoids must be disregarded as a possible indirect cause for the inhibition of the oxidative species. One possible mechanism for the inhibition of *O2-, highly dependent on the substitution pattern of the flavonoid, may be the generation of hydroperoxides or dioxetanes as oxidation products, as already postulated for other biologically relevant compounds. The simultaneous OH-substitution on positions C3 and C7 of the flavonoid skeleton plays a definitive role in the enhancement of the *O2- inhibitory effect. The replacement of OH by a O-rutinosyl group on position C7 suppresses at all that effect, whereas the absence of an OH group in position 7 significantly reduces the antioxidative power. Finally, the presence of OH groups on positions 3'and 4' does not produce any determinant effect in the antioxidative behaviour of the flavonoids.